All-Bio Science Inc. Announces Board Approval of Q1 2026 Consolidated Financial Statements

1. Date of report to the Board of Directors or Board resolution: 2026/05/07 2. Date of Audit Committee approval: 2026/05/07 3. Reporting period for financial statements or unaudited annual financial information: Start and end dates (YYYY/MM/DD~YYYY/MM/DD): 2026/01/01~2026/03/31 4. Cumulative operating revenue from January 1 to the end of the current period (NT$ thousands): 2823 5. Cumulative operating gross profit (loss) from January 1 to the end of the current period (NT$ thousands): -320 6. Cumulative operating profit (loss) from January 1 to the end of the current period (NT$ thousands): -83470 7. Cumulative pre-tax net profit (loss) from January 1 to the end of the current period (NT$ thousands): -75995 8. Cumulative net profit (loss) for the current period from January 1 to the end of the current period (NT$ thousands): -75995 9. Cumulative net profit (loss) attributable to owners of the parent company from January 1 to the end of the current period (NT$ thousands): -65328 10. Cumulative basic earnings (loss) per share from January 1 to the end of the current period (NT$): -0.5 11. Total assets at the end of the period (NT$ thousands): 1728169 12. Total liabilities at the end of the period (NT$ thousands): 47111 13. Equity attributable to owners of the parent company at the end of the period (NT$ thousands): 1593094 14. Other matters that need to be specified: None